Results 51 to 60 of about 4,529 (167)
Health Science Reports, Volume 9, Issue 9, September 2026.ABSTRACT Background and Aims Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, encompassing coronary artery disease, hypertension, heart failure, and cerebrovascular disorders. The global burden of CVD continues to rise, driven by complex interactions among endothelial dysfunction, oxidative stress, inflammation,
Nawfal Hasan Siam +8 more
wiley +1 more source
Haseki Tıp Bülteni, 2018 Aim:During reperfusion of myocardial ischemia, damage can also be seen in the kidneys. Although many studies have been conducted on the underlying mechanisms, the basic mechanism of this interaction is still unknown.
Güldem Mercanoğlu +3 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Review is devoted to the role of modern beta-blocker nebivolol in the treatment of stable ischemic heart disease (IHD). The mode of nebivolol anti-ischemic activity is considered, as well as its use particularities in IHD patients with different ...
V. P. Lupanov
doaj +1 more source
Acta Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen +3 more
wiley +1 more source
A review of the safety and efficacy of nebivolol in the mildly hypertensive patient
Vascular Health and Risk Management, 2008 John CockcroftWales Heart Research Institute, University Hospital Heath Park, Cardiff, UKAbstract: Nebivolol is a third generation beta-blocker, which can be distinguished from other beta-blockers by its hemodynamic profile.
John Cockcroft
doaj
Рациональная фармакотерапия в кардиологии, 2016 Aim. To compare effects of 12-month monotherapy with nebivolol, enalapril and indapamide on blood pressure (BP), left ventricular hypertrophy and quality of life in the locomotive engineers and their assistants with stress-associated hypertension at the ...
О. N. Antropova +4 more
doaj +1 more source
Nebivolol-induced gynecomastia
Journal of Pharmacology and Pharmacotherapeutics, 2015 Adverse drug reactions play a substantial role in the etiology of gynecomastia. Gynecomastia as an adverse drug reaction, related to some cardiovascular drugs, has been reported in literature. Nebivolol is a third generation beta-blocker, and gynecomastia as an adverse effect on the consumption of this drug has not been reported in any article yet.
Köklü, Erkan +4 more
openaire +3 more sources
Journal of International Medical Research, 2020 Purpose Our meta-analysis was undertaken to evaluate the efficacy and safety of nebivolol compared with other second-generation β blockers for hypertensive patients.
Jun-Ying Liu +6 more
doaj +1 more source
EFFICACY AND TOLERABILITY OF NEBIVOLOL COMPARED WITH OTHER ANTIHYPERTENSIVE DRUGS: A META-ANALYSIS
Российский кардиологический журнал, 2011 Aim: Lowering BP to normal levels without quality of life deterioration is the most important means of reducing cardiovascular risk. Recent studies have challenged the position of beta-adrenoreceptor antagonists (beta-blockers) as first-line ...
L. M. Van Bortel +2 more
doaj
Discover ChemistryNebivolol, a beta-blocker commonly prescribed for the treatment of hypertension and heart failure, functions by decelerating heart rate and promoting vasodilation, thereby enhancing blood flow and reducing blood pressure.
Kurdo A. Abdullah +4 more
doaj +1 more source